| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 3844 | 2020 |
| What's in a name? Renaming ‘NAFLD’to ‘MAFLD’ Y Fouad, I Waked, S Bollipo, A Gomaa, Y Ajlouni, D Attia Liver international 40 (6), 1254-1261, 2020 | 352 | 2020 |
| Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms YM Fouad, PO Katz, JG Hatlebakk, DO Castell Official journal of the American College of Gastroenterology| ACG 94 (6 …, 1999 | 278 | 1999 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 216 | 2022 |
| Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa G Shiha, K Alswat, M Al Khatry, AI Sharara, N Örmeci, I Waked, ... The lancet Gastroenterology & hepatology 6 (1), 57-64, 2021 | 153 | 2021 |
| History of nonalcoholic fatty liver disease A Lonardo, S Leoni, KA Alswat, Y Fouad International Journal of Molecular Sciences 21 (16), 5888, 2020 | 151 | 2020 |
| Hepato-cardiac disorders YM Fouad, R Yehia World journal of hepatology 6 (1), 41, 2014 | 150 | 2014 |
| Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease G Feng, L Valenti, VWS Wong, YM Fouad, Y Yilmaz, W Kim, G Sebastiani, ... Nature Reviews Gastroenterology & Hepatology 21 (1), 46-56, 2024 | 96 | 2024 |
| The NAFLD‐MAFLD debate: eminence vs evidence Y Fouad, R Elwakil, M Elsahhar, E Said, S Bazeed, A Ali Gomaa, ... Liver International 41 (2), 255-260, 2021 | 96 | 2021 |
| Oesophageal motility defects associated with nocturnal gastro‐oesophageal reflux on proton pump inhibitors Fouad, Castell Alimentary pharmacology & therapeutics 13 (11), 1467-1471, 1999 | 80 | 1999 |
| Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists Y Fouad, A Gomaa, N Semida, WA Ghany, D Attia Journal of hepatology 74 (5), 1254-1256, 2021 | 71 | 2021 |
| A global research priority agenda to advance public health responses to fatty liver disease JV Lazarus, HE Mark, AM Allen, JP Arab, P Carrieri, M Noureddin, ... Journal of hepatology 79 (3), 618-634, 2023 | 69 | 2023 |
| Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis MA Sharawey, EM Shawky, LH Ali, AA Mohammed, HA Hassan, ... Hepatology international 5, 927-933, 2011 | 61 | 2011 |
| An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease DQ Sun, G Targher, CD Byrne, DC Wheeler, VWS Wong, JG Fan, H Tilg, ... Hepatobiliary surgery and nutrition 12 (3), 386, 2023 | 52 | 2023 |
| Barrett’s esophagus: prevalence and risk factors in patients with chronic GERD in Upper Egypt YM Fouad, MM Makhlouf, HM Tawfik, H El Amin, WA Ghany, ... World journal of gastroenterology: WJG 15 (28), 3511, 2009 | 49 | 2009 |
| The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experience HR El‐Khayat, EM Kamal, MH El‐Sayed, M El‐Shabrawi, H Ayoub, ... Alimentary pharmacology & therapeutics 47 (6), 838-844, 2018 | 48 | 2018 |
| The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD CW Spearman, H Desalegn, P Ocama, YA Awuku, O Ojo, M Elsahhar, ... Journal of hepatology 74 (5), 1256-1258, 2021 | 47 | 2021 |
| Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4 H El‐Khayat, Y Fouad, HI Mohamed, H El‐Amin, EM Kamal, M Maher, ... Alimentary pharmacology & therapeutics 47 (5), 674-679, 2018 | 46 | 2018 |
| Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience HR El-Khayat, YM Fouad, M Maher, H El–Amin, H Muhammed Gut 66 (11), 2008-2012, 2017 | 45 | 2017 |
| Global burden of metabolic diseases, 1990–2021 H Zhang, XD Zhou, MD Shapiro, GYH Lip, H Tilg, L Valenti, VK Somers, ... Metabolism 160, 155999, 2024 | 38 | 2024 |
Ehab M Abdel Raheemlecturer ,tropical medicine.faculty of medicine ,minia university,EgyptEmail verificata su mu.edu.eg